Forty Seven, Inc. (FTSV)
(Delayed Data from NSDQ)
$18.35 USD
+0.35 (1.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[FTSV]
Reports for Purchase
Showing records 1 - 20 ( 64 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Can One of These Companies Compete for the CD47 Crown? Our Thoughts Following the Forty Seven Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Forty Seven Announces Buyout Agreement; Downgrade to Neutral with $95.50PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Not March Madness - Gilead Acquires Forty Seven
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Industry: Medical - Drugs
Tipping The Phagocytic Balance In the TME Is Important
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Industry: Medical - Drugs
Patient Selection in Solid Tumors Might Be the Key
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Industry: Medical - Drugs
CRC Data Indicate Anti-CD47 Synergy May Require Tumor Cell Stress
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Industry: Medical - Drugs
We See a Clear Path to Approval in MDS; Higher $51PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Synergy in CRC Appears Less Robust. Next - Early Data in Ovarian Cancer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Steady Progress Into a Catalyst-rich 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S